opioids
Latest
Pancreatic Opioids Regulate Ingestive and Metabolic Phenotypes
Neuromodulation of subjective experience
Many psychoactive substances are used with the aim of altering experience, e.g. as analgesics, antidepressants or antipsychotics. These drugs act on specific receptor systems in the brain, including the opioid, serotonergic and dopaminergic systems. In this talk, I will summarise human drug studies targeting opioid receptors and their role for human experience, with focus on the experience of pain, stress, mood, and social connection. Opioids are only indicated for analgesia, due to their potential to cause addiction. When these regulations occurred, other known effects were relegated to side effects. This may be the cause of the prevalent myth that opioids are the most potent painkillers, despite evidence from head-to-head trials, Cochrane reviews and network meta-analyses that opioids are not superior to non-opioid analgesics in the treatment of acute or chronic non-cancer pain. However, due to the variability and diversity of opioid effects across contexts and experiences, some people under some circumstances may indeed benefit from prolonged treatment. I will present data on individual differences in opioid effects due to participant sex and stress induction. Understanding the effects of these commonly used medications on other aspects of the human experience is important to ensure correct use and to prevent unnecessary pain and addiction risk.
The neural basis of pain experience and its modulation by opioids
How the brain creates a painful experience remains a mystery. Solving this mystery is crucial to understanding the fundamental biological processes that underlie the perception of body integrity, and to creating better, non-addictive pain treatments. My laboratory’s goal is to resolve the neural basis of pain. We aim to understand the mechanisms by which our nervous system produces and assembles the sensory-discriminative, affective-motivational, and cognitive-evaluative dimensions of pain to create this unique and critically important experience. To capture every component of the pain experience, we examine the entirety of the pain circuitry, from sensory and spinal ascending pathways to cortical/subcortical circuits and brainstem descending pain modulation systems, at the molecular, cellular, circuit and whole-animal levels. For these studies, we have invented novel behavioral paradigms to interrogate the affective and cognitive dimensions of pain in mice while simultaneously imaging and manipulating nociceptive circuits. My laboratory also investigates how opioids suppress pain. Remarkably, despite their medical and societal significance, how opium poppy alkaloids such as morphine produce profound analgesia remains largely unexplained. By identifying where and how opioids act in neural circuits, we not only establish the mechanisms of action of one of the oldest drugs known to humans, but also reveal the critical elements of the pain circuitry for developing of novel analgesics and bringing an end to the opioid epidemic.
The Kappa Opioid Receptor as Potential Drug Target in TLE
The Kappa Opioid Receptor as Potential Drug Target in TLE Over the last decades, neuropeptides and their receptors received increasing interest as drug targets for multiple purposes. Our interest focuses on the endogenous opioid system and more specifically on dynorphins and the kappa opioid receptor (KOR). Activation of KOR blocks presynaptic Calcium channels and facilitates postsynaptic Potassium release, thereby dampening signal transduction. As KORs are situated on excitatory neurons in the hippocampus, this makes them an interesting target in temporal lobe epilepsy.
New circuit for respiratory depression, anesthesia, and slow wave oscillations: Mu-opioids→MHb→IPN→DRN + PAG + MRN
FENS Forum 2024
Thalamic opioids from POMC satiety neurons gate sugar appetite
FENS Forum 2024
opioids coverage
6 items